Cybin completes acquisition of Small Pharma

23 October 2023

Team:

Peter Simeon, Warren Cass, Ovo Efemini, Kathleen Ritchie, Anita Nador, Jayde Wood, Brett Kagetsu, Ethan Chang, Jonathan Ross, Toni Vodola, Samantha Myers, Lee Nuttall, Rebecca Jones, Bernardine Adkins, James Stunt

On October 23, 2023, Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin") acquired Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) ("Small Pharma") by way of a plan of arrangement under the Business Corporations Act (British Columbia).

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Headquartered in Canada and founded in 2019, Cybin operates in Canada, the US, the UK, the Netherlands and Ireland.

The combination of Cybin and Small Pharma creates an international, clinical-stage leader with the potential to transform the treatment paradigm for mental health conditions. Cybin's and Small Pharma's combined N,N-dimethyltryptamine ("DMT") and deuterated DMT programs creates the largest dataset of systematic research on these short-duration psychedelic molecules. The companies' combined development portfolios are highly complementary and provide multiple opportunities to create operational and cost synergies.

Teams from Gowling WLG in Canada and the UK advised Cybin on this acquisition. In Canada the team included Peter Simeon, Warren Cass, Adam Sherman, Ovo Efemini, Kathleen Ritchie and Jacob Cawker (corporate/securities/M&A), Anita Nador and Jayde Wood (IP), Mariam Al-Shikarchy (tax), Brett Kagetsu and Ethan Chang (BC corporate law) and Jonathan Ross (advocacy), assisted by paralegal Toni Vodola. The UK team included Samantha Myers (corporate), Lee Nuttall (tax), Rebecca Jones (employment), Bernardine Adkins and James Stunt (trade and competition).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Life Sciences, Mergers & Acquisitions, Corporate Commercial, Intellectual Property Law, Tax, Employment, Labour & Equalities, International Trade and Customs